Type I interferons in host defence and inflammatory diseases
Type I interferons (IFN) can have dual and opposing roles in immunity, with effects that are beneficial or detrimental to the individual depending on whether IFN pathway activation is transient or sustained. Determinants of IFN production and its functional consequences include the nature of the mic...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-12-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/6/1/e000336.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850065101342638080 |
|---|---|
| author | Lars Rönnblom Mary K. Crow |
| author_facet | Lars Rönnblom Mary K. Crow |
| author_sort | Lars Rönnblom |
| collection | DOAJ |
| description | Type I interferons (IFN) can have dual and opposing roles in immunity, with effects that are beneficial or detrimental to the individual depending on whether IFN pathway activation is transient or sustained. Determinants of IFN production and its functional consequences include the nature of the microbial or nucleic acid stimulus, the type of nucleic acid sensor involved in inducing IFN, the predominant subtype of type I IFN produced and the immune ecology of the tissue at the time of IFN expression. When dysregulated, the type I IFN system drives many autoimmune and non-autoimmune inflammatory diseases, including SLE and the tissue inflammation associated with chronic infection. The type I IFN system may also contribute to outcomes for patients affected by solid cancers or myocardial infarction. Significantly more research is needed to discern the mechanisms of induction and response to type I IFNs across these diseases, and patient endophenotyping may help determine whether the cytokine is acting as ‘friend’ or ‘foe’, within a particular patient, and at the time of treatment. This review summarises key concepts and discussions from the second International Summit on Interferons in Inflammatory Diseases, during which expert clinicians and scientists evaluated the evidence for the role of type I IFNs in autoimmune and other inflammatory diseases. |
| format | Article |
| id | doaj-art-5d8ac73f37c14d5581ef6414db4cbe6b |
| institution | DOAJ |
| issn | 2053-8790 |
| language | English |
| publishDate | 2019-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Lupus Science and Medicine |
| spelling | doaj-art-5d8ac73f37c14d5581ef6414db4cbe6b2025-08-20T02:49:05ZengBMJ Publishing GroupLupus Science and Medicine2053-87902019-12-016110.1136/lupus-2019-000336Type I interferons in host defence and inflammatory diseasesLars Rönnblom0Mary K. Crow1Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, SwedenHospital for Special Surgery, Weill Cornell Medical College, Mary Kirkland Center for Lupus Research, United States of AmericaType I interferons (IFN) can have dual and opposing roles in immunity, with effects that are beneficial or detrimental to the individual depending on whether IFN pathway activation is transient or sustained. Determinants of IFN production and its functional consequences include the nature of the microbial or nucleic acid stimulus, the type of nucleic acid sensor involved in inducing IFN, the predominant subtype of type I IFN produced and the immune ecology of the tissue at the time of IFN expression. When dysregulated, the type I IFN system drives many autoimmune and non-autoimmune inflammatory diseases, including SLE and the tissue inflammation associated with chronic infection. The type I IFN system may also contribute to outcomes for patients affected by solid cancers or myocardial infarction. Significantly more research is needed to discern the mechanisms of induction and response to type I IFNs across these diseases, and patient endophenotyping may help determine whether the cytokine is acting as ‘friend’ or ‘foe’, within a particular patient, and at the time of treatment. This review summarises key concepts and discussions from the second International Summit on Interferons in Inflammatory Diseases, during which expert clinicians and scientists evaluated the evidence for the role of type I IFNs in autoimmune and other inflammatory diseases.https://lupus.bmj.com/content/6/1/e000336.full |
| spellingShingle | Lars Rönnblom Mary K. Crow Type I interferons in host defence and inflammatory diseases Lupus Science and Medicine |
| title | Type I interferons in host defence and inflammatory diseases |
| title_full | Type I interferons in host defence and inflammatory diseases |
| title_fullStr | Type I interferons in host defence and inflammatory diseases |
| title_full_unstemmed | Type I interferons in host defence and inflammatory diseases |
| title_short | Type I interferons in host defence and inflammatory diseases |
| title_sort | type i interferons in host defence and inflammatory diseases |
| url | https://lupus.bmj.com/content/6/1/e000336.full |
| work_keys_str_mv | AT larsronnblom typeiinterferonsinhostdefenceandinflammatorydiseases AT marykcrow typeiinterferonsinhostdefenceandinflammatorydiseases |